Align Technology (ALGN) Earnings Date & Reports

Align Technology posted total revenues of $1,040.1 million for Q1 2026, a 6.2% increase YoY, exceeding consensus estimates near $1.02 billion. Clear aligner revenues rose 7.4% YoY to $856.0 million, fueled by record volumes of 685.7 thousand cases (up 6.7% YoY), with double-digit growth in international regions like EMEA, APAC, and LATAM offsetting stable North America performance. Imaging Systems and CAD/CAM services revenues edged up 0.9% YoY to $184.1 million, impacted by seasonal capital equipment sales but buoyed by iTero Lumina scanner adoption.

GAAP diluted EPS was $1.57, up 21.0% YoY, while non-GAAP EPS reached $2.58, up 17.7% YoY and beating expectations by about 12-14%. Gross margins stood at 70.8% (GAAP) and 71.8% (non-GAAP), with operating margins at 13.6% (GAAP) and 21.5% (non-GAAP). The company highlighted higher volumes, average selling prices (ASPs), and operational efficiencies as key drivers exceeding its own outlook.

For Q2 2026, guidance calls for revenues of $1,040-$1,060 million (3-5% YoY growth), with flat ASPs and sequential volume increases. Fiscal 2026 guidance was reaffirmed at 3-4% revenue growth (mid-single-digit aligner volumes), non-GAAP operating margin around 23.7% (100 basis points improvement YoY), and capex of $125-150 million.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Following the Q1 2026 earnings release on April 29 after market close, Align Technology shares saw positive momentum in extended trading and early indications on April 30, reflecting approval of the EPS beat, record volumes, and reaffirmed guidance despite some FX headwinds. Investors focused on robust international growth and share repurchase activity as signs of confidence, though seasonal Systems revenue softness tempered enthusiasm. Sentiment remains optimistic on Align's innovation pipeline amid broader healthcare sector volatility.

Forward Outlook and Key Factors to Monitor

Align Technology's reaffirmed fiscal 2026 guidance points to modest 3-4% revenue growth, supported by mid-single-digit clear aligner volume increases and a foreign exchange tailwind of about 100 basis points. Investors should track Q2 execution, particularly clear aligner ASP stability and sequential volume ramps across patient demographics like teens and adults.

International markets, which drove double-digit growth in Q1, warrant close attention amid geopolitical risks in the Middle East—deemed immaterial now but flagged for potential patient traffic impacts. North American stability hinges on orthodontist and general dentist adoption, bolstered by digital workflow enhancements.

On the Systems side, monitor iTero scanner utilization and Lumina model uptake to offset seasonality. Margin trends will reflect operational efficiencies, FX moderation, and cost controls, targeting non-GAAP operating margin expansion to 23.7%. Upcoming catalysts include further share repurchases (up to $200 million in Q2) and innovation updates at industry events. Broader dynamics like tariff risks, macroeconomic pressures, and competition in direct-to-consumer aligners remain key variables.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations